Rebecca Chambers net worth and biography

Rebecca Chambers Biography and Net Worth

CFO of Veracyte

Rebecca Chambers joined Veracyte as Chief Financial Officer in 2021. Ms. Chambers has extensive healthcare leadership experience, previously serving as Chief Financial Officer for Outset Medical, a publicly traded medical technology company focused on reducing dialysis cost and complexity. Prior to Outset Medical, she served in several financial leadership roles at Illumina, including Vice President of Financial Planning and Analysis and Vice President of Investor Relations and Treasury. She has also served as Head of Investor Relations and Corporate Communications at Myriad Genetics. Earlier in her career, Ms. Chambers held various roles in investor relations at Life Technologies (now part of Thermo Fisher Scientific), served as a Vice President at Bank of America and as a Senior Research Associate at Millennium Pharmaceuticals (now part of Takeda Pharmaceuticals). Ms. Chambers serves on the board of Inari Medical, a medical device company focused on venous diseases. She holds a B.S. in Biology from John Carroll University and an M.B.A. from the S.C. Johnson Graduate School of Management at Cornell University.

What is Rebecca Chambers' net worth?: The estimated net worth of Rebecca Chambers is at least $3.42 million as of February 3rd, 2025. Ms. Chambers owns 113,510 shares of Veracyte stock worth more than $3,418,921 as of March 30th. This net worth approximation does not reflect any other investments that Ms. Chambers may own. Additionally, Ms. Chambers receives an annual salary of $901,490.00 as CFO at Veracyte. Learn More about Rebecca Chambers' net worth.
How old is Rebecca Chambers?: Ms. Chambers is currently 46 years old. There are 6 older executives and no younger executives at Veracyte. The oldest executive at Veracyte is Dr. Phillip G. Febbo M.D., Chief Scientific & Medical Officer, who is 58 years old. Learn More on Rebecca Chambers' age.
What is Rebecca Chambers' salary?: As the CFO of Veracyte, Inc., Ms. Chambers earns $901,490.00 per year. There are 2 executives that earn more than Ms. Chambers. The highest earning executive at Veracyte is Mr. Marc A. Stapley, CEO & Director, who commands a salary of $1,550,000.00 per year. Learn More on Rebecca Chambers' salary.
How do I contact Rebecca Chambers?: The corporate mailing address for Ms. Chambers and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at keith@veracyte.com. Learn More on Rebecca Chambers' contact information.
Has Rebecca Chambers been buying or selling shares of Veracyte?: Within the last three months, Rebecca Chambers has sold $23,108.95 of Veracyte stock. Most recently, Rebecca Chambers sold 527 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $43.85, for a transaction totalling $23,108.95. Following the completion of the sale, the chief financial officer now directly owns 113,510 shares of the company's stock, valued at $4,977,413.50. Learn More on Rebecca Chambers' trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Rebecca Chambers (CFO), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), Marc Stapley (CEO & Director), Jonathan Wygant (CAO), and Jonathan Wygant (CAO). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 17 times. They sold a total of 88,392 shares worth more than $2,810,829.26. The most recent insider tranaction occured on February, 3rd when CFO Rebecca Chambers sold 527 shares worth more than $23,108.95. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 2/3/2025.

Rebecca Chambers Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/3/2025	Sell	527	$43.85	$23,108.95	113,510
12/3/2024	Sell	7,000	$43.23	$302,610.00	114,037

Rebecca Chambers Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Today's Range

Now: $30.12

$29.65

$31.07

50 Day Range

MA: $37.57

$30.12

$46.14

2 Week Range

Now: $30.12

$18.61

$47.32

Volume

710,014 shs

Average Volume

835,914 shs

Market Capitalization

$2.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

Rebecca Chambers Biography and Net Worth

What is Rebecca Chambers' net worth?

How old is Rebecca Chambers?

What is Rebecca Chambers' salary?

How do I contact Rebecca Chambers?

Has Rebecca Chambers been buying or selling shares of Veracyte?

Who are Veracyte's active insiders?

Are insiders buying or selling shares of Veracyte?